- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.11. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 25.11. | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | Xilio Therapeutics GAAP EPS of -$0.11 misses by $0.08, revenue of $19.07M beats by $0.43M | 2 | Seeking Alpha | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results | 2.140 | GlobeNewswire (Europe) | Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presented... ► Artikel lesen | |
| 13.11. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Xilio presents promising data for tumor-activated immunotherapies | 5 | Investing.com | ||
| 07.11. | Xilio reports 40% response rate in colorectal cancer treatment study | 2 | Investing.com | ||
| 07.11. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual ... | 880 | GlobeNewswire (Europe) | 40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing... ► Artikel lesen | |
| 07.11. | Xilio Therapeutics, Inc.: Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 07.11. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.11. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 5 | GlobeNewswire (USA) | ||
| 30.10. | Xilio to present vilastobart phase 2 data at SITC annual meeting | 1 | Investing.com | ||
| 30.10. | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 03.10. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 03.10. | Xilio Therapeutics wechselt am Montag an den Nasdaq Capital Market | 2 | Investing.com Deutsch | ||
| 03.10. | Xilio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.10. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 137 | GlobeNewswire (Europe) | WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 09.09. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License ... | 683 | GlobeNewswire (Europe) | Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first... ► Artikel lesen | |
| 09.09. | Xilio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.08. | Xilio Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NURIX THERAPEUTICS | 18,520 | +2,83 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | +0,73 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock | ||
| SUMMIT THERAPEUTICS | 17,820 | +4,58 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| RELAY THERAPEUTICS | 8,400 | +3,32 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| IMMUNEERING | 5,650 | -0,35 % | Immuneering Corporation: Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | - End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 -... ► Artikel lesen | |
| QIAGEN | 38,740 | +0,77 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,010 | +6,73 % | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | ||
| VIR BIOTECHNOLOGY | 5,760 | -2,87 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | +0,26 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ABSCI | 3,380 | -0,88 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,580 | +4,43 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| VOR BIOPHARMA | 12,410 | -3,05 % | Vor Biopharma Inc. - 8-K, Current Report |
XILIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,670 Euro und damit +3,09 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.